앱시(ABSI)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $9.65 (+4.10%), 시가총액 $0.76B, 52주 최저~최고 $2.30 ~ $5.95.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The
앱시의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
앱시의 현재 주가는 $9.65 (+4.10%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
앱시의 시가총액은 약 $0.76B입니다.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 cl